Company
Design Therapeutics, Inc. (DSGN)
Standardized SEC financial data for Design Therapeutics, Inc. — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0001807120 · NASDAQ · Pharmaceutical Preparations.
Return on equity
-32.8%
Free cash flow
-$54.6M
Current ratio
17.14×
EPS (diluted)
$-1.22
Ratios for fiscal year 2025, standardized from SEC filings.
Income statement
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $226K | — | — | — | $0 | $0 |
| R&D expense |
Balance sheet
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.4M | $384.1M | $330.4M | $281.8M | $245.5M | $219.8M |
| Total current assets |
Get DSGN data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/DSGN/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/DSGN/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"